Combination of (131)I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model

Lanatoside C has a promising anti-tumor activity and is a potential candidate for radiosensitizers. In this study, we have investigated the therapeutic efficacy of the combination of (131)I-trastuzumab and lanatoside C for inhibition of human epidermal growth factor receptor 2 (HER2) positive tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Vinod, Nagarajan, Kim, Jae Hyung, Choi, Seungbum, Lim, Ilhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213814/
https://www.ncbi.nlm.nih.gov/pubmed/34145369
http://dx.doi.org/10.1038/s41598-021-92460-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213814/
https://www.ncbi.nlm.nih.gov/pubmed/34145369
http://dx.doi.org/10.1038/s41598-021-92460-0

Ejemplares similares